Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
Shanghai Junshi Biosciences' anti-PD-1 monoclonal antibody, Toripalimab, announces Phase 3 trial data for the treatment of small-cell lung cancer
24 October 2023
The 2023 ESMO congress selected Shanghai Junshi Biosciences' phase III trial, EXTENTORCH, on anti-PD-1 monoclonal antibody toripalimab for the LBA.
Drug Insights
4 min read
A Comprehensive Review of peginterferon beta-1a's R&D Innovations and Drug Target Mechanism
24 October 2023
This article summarized the latest R&D progress of peginterferon beta-1a, the Mechanism of Action for peginterferon beta-1a, and the drug target R&D trends for peginterferon beta-1a.
Valuable Targets
3 min read
Analysis on the Clinical Research Progress of AMPK Inhibitor
24 October 2023
AMP-activated protein kinase (AMPK) is a crucial enzyme that plays a central role in regulating energy balance within the human body.
Drug Insights
4 min read
Pharmaceutical Insights: pimavanserin tartrate's R&D Progress and its Mechanism of Action on Drug Target
24 October 2023
This article summarized the latest R&D progress of pimavanserin tartrate, the Mechanism of Action for pimavanserin tartrate, and the drug target R&D trends for pimavanserin tartrate.
Bio Sequence
5 min read
Biological Glossary | What is Artificial Sequence?
24 October 2023
An artificial sequence is a sequence that is not naturally occurring but created by human manipulation.
Drug Insights
5 min read
Exploring polatuzumab vedotin-piiq's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
24 October 2023
This article summarized the latest R&D progress of polatuzumab vedotin-piiq, the Mechanism of Action for polatuzumab vedotin-piiq, and the drug target R&D trends for polatuzumab vedotin-piiq.
Latest Hotspot
3 min read
CStone Pharmaceuticals releases Phase 3 GEMSTONE-303 clinical trial data of anti-PD-L1 monoclonal antibody sugemalimab, for the treatment of gastric cancer
24 October 2023
The GEMSTONE-303 Phase III trial of CStone Pharmaceuticals' sugemalimab was selected for an LBA report at the 2023 ESMO conference.
Drug Insights
4 min read
Decoding primaquine phosphate: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
24 October 2023
This article summarized the latest R&D progress of primaquine phosphate, the Mechanism of Action for primaquine phosphate, and the drug target R&D trends for primaquine phosphate.
Bio Sequence
2 min read
Biological Glossary | What is Aptamer?
24 October 2023
Aptamers are single-stranded DNA or RNA molecules that bind to a specific target molecule.
Drug Insights
4 min read
Deep Scientific Insights on procaine hydrochloride's R&D Progress, Mechanism of Action, and Drug Target
24 October 2023
This article summarized the latest R&D progress of procaine hydrochloride, the Mechanism of Action for procaine hydrochloride, and the drug target R&D trends for procaine hydrochloride.
Valuable Targets
4 min read
Advances in Clinical Research on Acetylcholinesterase Inhibitor
23 October 2023
AChE is responsible for breaking down the neurotransmitter acetylcholine, which is involved in various physiological processes such as muscle contraction, cognition, and memory.
Drug Insights
5 min read
An In-depth Analysis of proxalutamide's R&D Progress and Mechanism of Action on Drug Target
23 October 2023
This article summarized the latest R&D progress of proxalutamide, the Mechanism of Action for proxalutamide, and the drug target R&D trends for proxalutamide.